Caribou Biosciences generated $3941000 in licensing and collaboration revenue in the fourth quarter of 2025 while reporting a net loss of $26488000. Operating expenses declined year over year as research and development and general administrative spending decreased following workforce reductions and pipeline prioritization.
Licensing and collaboration revenue reached $3941000 in Q4 2025.
Net loss improved to $26488000 compared with $35490000 in Q4 2024.
Research and development expenses were reduced to $23815000.
Total operating expenses declined to $32394000 during the quarter.
Caribou expects its current cash, cash equivalents, and marketable securities to fund operations into the second half of 2027 while advancing key CAR-T programs and preparing for a potential pivotal trial for vispa-cel.
Analyze how earnings announcements historically affect stock price performance